Reason is co-founder and CEO of Repair Biotechnologies. He has been an active angel investor in the longevity industry since its earliest days, with investments including Oisin Biotechnologies and Leucadia Therapeutics. He is a long-standing and well-connected patient advocate for aging research, involved in numerous fundraising and outreach initiatives conducted by organizations such as the Methuselah Foundation and SENS Research Foundation since the early 2000s. He is also the founder and writer of Fight...
Reason, CEO of Repair Biotechnologies, brought an extended complaint about gene therapy to the stage. Gene therapy is the process of replacing or altering the genome within cells, and has the potential to solve all sorts of pathologies. It could also let us figure out the core mechanics of aging, but all the current methods of gene therapy are too flimsy to use properly. We need a gene therapy that works 8-out-of-10 times, something robust and reliable. Critical features of such a therapy would include tissue or cell specific targeting, access to the nucleus or mitochondria, low immunogenicity, and tunable duration of expression.